ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2098

NRF2 Downregulates Inflammation and Protects Against Autoimmune Lung Disease in Experimental Lupus

Shuhong Han1, Haoyang Zhuang1, Pui Lee2, Lijun Yang3 and Westley Reeves1,4, 1Medicine, University of Florida, Gainesville, FL, 2Harvard Medical School, Boston, MA, 3Pathology, Immunology and laboratory medicine, University of Florida, Gainesville, FL, 4Division of Rheumatology & Clinical Immunology, University of Florida, Gainesville, FL

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Macrophage, ROS and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Systemic Lupus Erythematosus – Animal Models Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The transcription factor nuclear factor erythroid 2-related factor (Nrf2) is a master regulator of genes involved in cellular defense against oxidative and electrophilic stresses. It forms a cytoplasmic complex with the ubiquitin ligase KEAP1 and CUL3, which in unstressed conditions promote the ubiquitin-mediated degradation of Nrf2. Modification of the reactive cysteine residues of KEAP1 by electrophiles or ROS reduces the ubiquitin ligase activity of KEAP1/CUL3, resulting in Nrf2 stabilization and binding to antioxidant response elements (AREs) in the promoters of target genes. As there is functional cross-talk between Nrf2 and NF-κB mediated inflammatory responses, we hypothesized that Nrf2 might downregulate chronic inflammation in mice with diffuse alveolar hemorrhage (DAH) associated with pristane-induced lupus, a disease driven by macrophages (Mϕ).

Methods: Murine Mϕ subsets were analyzed by flow cytometry and the cell subsets were flow-sorted. Binding of Nrf2 to its target sequence was determined in vitro. Gene expression in sorted Mϕ from pristane or mineral oil (MO) treated mice was determined using RNA-Seq and real-time PCR. Pristane-treated C57BL/6 mice received injections of CDDO-imidazolide every other day, a potent inducer of Nrf2/ARE signaling, or vehicle, starting 3-days after pristane treatment. DAH was assessed on day-14.

Results: Mϕ extracts from pristane-treated B6 mice exhibited lower Nrf2 binding in vitro to AREs vs. extracts from MO-treated controls. RNA-Seq showed that a series of Nrf2-regulated genes involved in the response to oxidative stress were expressed at lower levels in Mϕ from pristane vs. MO-treated mice. Low expression levels were confirmed by real-time PCR and Mϕ from pristane-treated mice had increased mitochondrial superoxide (MitoSox red staining), decreased mitochondrial membrane potential (tetramethylrhodamine staining), and increased cellular ROS (dichlorofluorescein diacetate staining) vs. controls. In vivo injection of CDDO-imidazolide decreased the number of CD11b+Ly6Chi (inflammatory) Mϕ, increased CD11b+CD138+ (pro-resolving) Mϕ, and reversed the pristane-induced changes in mitochondrial superoxide and cellular ROS while restoring mitochondrial membrane potential. Finally, CDDO-imidazolide treatment greatly attenuated the severity of DAH in pristane-treated mice (P<0.0001). A less potent Nrf2 activator, diethylmaleate, also was protective and reduced Mϕ TNFα production.

Conclusion: These observations suggest that oxidative stress is involved in the pathogenesis of chronic inflammation experimental lupus and that pharmacological Nrf2 activation can protect lupus mice from fatal lung hemorrhage.


Disclosure: S. Han, None; H. Zhuang, None; P. Lee, None; L. Yang, None; W. Reeves, None.

To cite this abstract in AMA style:

Han S, Zhuang H, Lee P, Yang L, Reeves W. NRF2 Downregulates Inflammation and Protects Against Autoimmune Lung Disease in Experimental Lupus [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/nrf2-downregulates-inflammation-and-protects-against-autoimmune-lung-disease-in-experimental-lupus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nrf2-downregulates-inflammation-and-protects-against-autoimmune-lung-disease-in-experimental-lupus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology